UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39661 Atea Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaw ...

Financial Performance - Atea Pharmaceuticals reported cash, cash equivalents, and marketable securities of $482.8 million as of September 30, 2024, down from $502.2 million at June 30, 2024[12]. - Research and development expenses decreased by $2.0 million to $26.2 million for Q3 2024, primarily due to lower external spending related to the COVID-19 Phase 3 trial[13]. - General and administrative expenses decreased by $1.6 million to $11.0 million for Q3 2024, mainly due to lower professional fees[14]. - The company reported a net loss of $31.2 million for Q3 2024, compared to a net loss of $33.1 million for Q3 2023[16]. Clinical Development - Atea expects to report topline Phase 2 SVR12 results from its HCV combination study in early December 2024, with 275 treatment-naïve patients enrolled[3]. - The Phase 2 study showed a 97% SVR12 rate in non-cirrhotic patients from the lead-in cohort, with a 100% SVR12 rate in genotype 3 patients[4]. - Atea is planning an End of Phase 2 meeting with the FDA in Q1 2025 to support the initiation of the Phase 3 program[5]. - Atea is developing a fixed-dose combination tablet to reduce the daily pill count from four to two, enhancing patient convenience[6]. - The company will present new data at The Liver Meeting 2024 and the American College of Pharmacometrics meeting, showcasing the effectiveness of bemnifosbuvir and ruzasvir[7][8]. - Atea is anticipating the topline results from its Phase 2 trial of the combination of bemnifosbuvir and ruzasvir for HCV treatment[21]. - The company plans to meet with the FDA regarding the potential initiation of the HCV Phase 3 program[21]. Market Outlook - The global HCV commercial market is projected to exceed $3 billion, with the U.S. accounting for approximately half of this market[2]. Forward-Looking Statements - Atea's forward-looking statements are based on current expectations and various assumptions, which are inherently uncertain[21]. - Actual results may differ materially from the forward-looking statements due to dependence on the success of Atea's advanced product candidates[21]. - Important factors affecting actual results are discussed under the "Risk Factors" section in Atea's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024[21].

Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4’24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases’ (AASLD’s) The Liver Meeting 2024 Pharmacokinetic Data for Bemnifosbuvir to be Presented at American College of Pharmacometrics Meeting Conference Call at 4:30 pm ET Today BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmac ...

Core Insights - Atea Pharmaceuticals is advancing the combination of bemnifosbuvir and ruzasvir as a potential treatment for Hepatitis C Virus (HCV), with upcoming presentations at The Liver Meeting 2024 [1][2] Company Overview - Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies for serious viral infections, leveraging a proprietary nucleos(t)ide prodrug platform [7] Product Development - Bemnifosbuvir is a nucleotide analog polymerase inhibitor that has shown to be approximately 10-fold more active than sofosbuvir against various HCV strains and has a favorable pharmacokinetic profile supporting once-daily dosing [3] - Ruzasvir, an NS5A inhibitor, has demonstrated potent antiviral activity and a favorable safety profile in clinical studies, also supporting once-daily dosing [4] Clinical Trials - The combination of bemnifosbuvir and ruzasvir is currently in Phase 2 development for HCV, with results expected to be reported later this year and plans to advance into Phase 3 development [2][8] Market Need - The high incidence rate of HCV infections highlights the urgent need for new therapies, particularly for patients with substance abuse disorders and comorbidities [2][5] - Globally, an estimated 50 million people live with chronic HCV infection, with around 1 million new infections and 242,000 deaths annually [5][6]

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Clipper Realty Inc. (CLPR) : This real estate company has seen the Zacks Consensus Estimate for its current year earnings increasing 43.6% over the last 60 days.REE Automotive Ltd. (REE) : This automotive technology company has seen the Zacks Consensus Estimate for its current year earnings increasing 46.3% over the last 60 days.Harmony Gold Mining Company Limited (HMY) : This gold-mining company has seen the Zacks Consensus Estimate fo ...

Core Viewpoint - Atea Pharmaceuticals, Inc. (AVIR) is experiencing significant selling pressure but is positioned for a potential trend reversal due to being in oversold territory and positive earnings outlook from analysts [1]. Group 1: Stock Performance - AVIR's stock has declined by 8% over the past four weeks, indicating a downward trend [1]. - The Relative Strength Index (RSI) for AVIR is currently at 29.61, suggesting that the stock is oversold and may be due for a rebound [4]. Group 2: Analyst Sentiment - There is strong consensus among Wall Street analysts that AVIR will report better earnings than previously predicted, with a 13% increase in the consensus EPS estimate over the last 30 days [4]. - AVIR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [5].

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Atea Pharmaceuticals, Inc. (AVIR) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Atea Pharmaceuticals, Inc. is a member of our Medical group, which includes 1017 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks ...

BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that data highlighting the metabolic activation pathway of bemnifosbuvir were published in the peer-reviewed journal, PLOS Biology, in an article titled, “The activation cascade of the broad-spectrum antiviral bemnifosbuvir characterized at atomic resolution. ...

Atea Pharmaceuticals, Inc. (AVIR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Sin ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Atea Pharmaceuticals, Inc. (AVIR) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Atea Pharmaceuticals, Inc. is one of 1021 companies in the Medical group. The Medical group currently sits at #3 within the Zack ...